MX2018015599A - Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. - Google Patents
Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer.Info
- Publication number
- MX2018015599A MX2018015599A MX2018015599A MX2018015599A MX2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A MX 2018015599 A MX2018015599 A MX 2018015599A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion protein
- sequence
- respect
- enveloped virus
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18151—Methods of production or purification of viral material
- C12N2760/18152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504120P | 2017-05-10 | 2017-05-10 | |
| PCT/US2018/032018 WO2018209052A1 (en) | 2017-05-10 | 2018-05-10 | Enveloped virus resistant to complement inactivation for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015599A true MX2018015599A (es) | 2019-05-16 |
Family
ID=64105722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015599A MX2018015599A (es) | 2017-05-10 | 2018-05-10 | Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11274141B2 (https=) |
| EP (1) | EP3621635A4 (https=) |
| JP (1) | JP7161940B2 (https=) |
| KR (3) | KR20250118857A (https=) |
| CN (3) | CN121343934A (https=) |
| AU (1) | AU2018265258B2 (https=) |
| BR (1) | BR112018075281A2 (https=) |
| CA (1) | CA3026892A1 (https=) |
| IL (1) | IL263979B2 (https=) |
| MX (1) | MX2018015599A (https=) |
| NZ (1) | NZ748798A (https=) |
| WO (1) | WO2018209052A1 (https=) |
| ZA (1) | ZA201808040B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN112759654A (zh) * | 2019-11-06 | 2021-05-07 | 深圳普菲科生命科技有限公司 | 一种病毒囊膜蛋白装配系统及其方法和应用 |
| EP4107187A4 (en) | 2020-02-21 | 2024-07-03 | Pandion Operations, Inc. | TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR |
| US20240067936A1 (en) * | 2021-02-26 | 2024-02-29 | Sillajen, Inc. | Oncolytic virus and uses thereof |
| CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
| KR20240003051A (ko) * | 2022-06-29 | 2024-01-08 | 신라젠(주) | Cd55 및 cd59를 동시 발현하는 항암 바이러스 |
| KR20240035360A (ko) * | 2022-09-07 | 2024-03-15 | 신라젠(주) | 항암 바이러스의 신규 용도 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| CA2161671A1 (en) | 1993-04-30 | 1994-11-10 | Robert M. Lorence | Methods of treating and detecting cancer using viruses |
| JPH10313865A (ja) * | 1997-05-15 | 1998-12-02 | Deinabetsuku Kenkyusho:Kk | ヒト補体制御因子が呈示されたベクター |
| US6475756B1 (en) * | 1997-11-21 | 2002-11-05 | Gesellschaft Fuer Biotechnologische Forschung Mbh(Gbf) | Development of viruses resistant to inactivation by the human complement system |
| JP4544497B2 (ja) | 1997-12-22 | 2010-09-15 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 異種融合タンパク質を有する組変えラブドウイルス |
| NZ507063A (en) * | 1998-04-02 | 2003-11-28 | Rigel Pharmaceuticals Inc | Self-dimerising peptides causing the formation of compact structures |
| IL145899A0 (en) | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
| AU2003298650B2 (en) * | 2002-11-15 | 2010-03-11 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
| CA2574282A1 (en) | 2004-07-21 | 2006-03-02 | Dana-Farber Cancer Institute, Inc. | Lentiviral vectors and uses thereof |
| JP5050198B2 (ja) * | 2006-09-05 | 2012-10-17 | 国立大学法人大阪大学 | ヒト補体制御因子発現遺伝子およびその利用 |
| WO2008118258A2 (en) * | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| JP5332064B2 (ja) * | 2007-03-01 | 2013-11-06 | ウェルスタット イムノセラピューティクス， エルエルシー | 炎症により特徴付けられる疾患の治療 |
| US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
| US20140206850A1 (en) | 2011-04-29 | 2014-07-24 | Keygene N.V. | Glyphosate resistance enhancement |
| EP2704744B1 (en) | 2011-05-05 | 2019-04-24 | Wellstat ImmunoTherapeutics, LLC | Complement factor b analogs and their uses |
| ES2651521T3 (es) * | 2011-12-01 | 2018-01-26 | Innovent Biologics, Inc. | Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| DK3143134T3 (da) * | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| RS61907B1 (sr) | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| GB201507119D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
| AU2016274989A1 (en) | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
| WO2017197525A1 (en) | 2016-05-19 | 2017-11-23 | Evgin Laura | Pseudotyped oncolytic rhabdoviruses and their use in combination therapy |
-
2018
- 2018-05-10 US US16/303,729 patent/US11274141B2/en active Active
- 2018-05-10 CA CA3026892A patent/CA3026892A1/en active Pending
- 2018-05-10 KR KR1020257024807A patent/KR20250118857A/ko active Pending
- 2018-05-10 KR KR1020247013722A patent/KR102839445B1/ko active Active
- 2018-05-10 JP JP2018564966A patent/JP7161940B2/ja active Active
- 2018-05-10 CN CN202511447107.5A patent/CN121343934A/zh active Pending
- 2018-05-10 BR BR112018075281-9A patent/BR112018075281A2/pt unknown
- 2018-05-10 NZ NZ748798A patent/NZ748798A/en unknown
- 2018-05-10 CN CN201880002553.7A patent/CN109414483B/zh active Active
- 2018-05-10 CN CN202511447108.XA patent/CN121343935A/zh active Pending
- 2018-05-10 EP EP18798575.9A patent/EP3621635A4/en active Pending
- 2018-05-10 KR KR1020187037869A patent/KR102662049B1/ko active Active
- 2018-05-10 MX MX2018015599A patent/MX2018015599A/es unknown
- 2018-05-10 WO PCT/US2018/032018 patent/WO2018209052A1/en not_active Ceased
- 2018-05-10 IL IL263979A patent/IL263979B2/en unknown
- 2018-05-10 AU AU2018265258A patent/AU2018265258B2/en active Active
- 2018-11-28 ZA ZA2018/08040A patent/ZA201808040B/en unknown
-
2022
- 2022-02-18 US US17/674,990 patent/US20220169701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL263979A (en) | 2019-02-28 |
| EP3621635A4 (en) | 2021-02-24 |
| CA3026892A1 (en) | 2018-11-15 |
| JP7161940B2 (ja) | 2022-10-27 |
| CN121343935A (zh) | 2026-01-16 |
| IL263979B2 (en) | 2023-09-01 |
| JP2020519230A (ja) | 2020-07-02 |
| EP3621635A1 (en) | 2020-03-18 |
| KR20250118857A (ko) | 2025-08-06 |
| CN121343934A (zh) | 2026-01-16 |
| RU2018146446A3 (https=) | 2021-09-10 |
| NZ748798A (en) | 2026-03-27 |
| ZA201808040B (en) | 2019-09-25 |
| KR20240073085A (ko) | 2024-05-24 |
| CN109414483B (zh) | 2025-10-24 |
| US20190194292A1 (en) | 2019-06-27 |
| IL263979B1 (en) | 2023-05-01 |
| CN109414483A (zh) | 2019-03-01 |
| US11274141B2 (en) | 2022-03-15 |
| KR102839445B1 (ko) | 2025-07-28 |
| BR112018075281A2 (pt) | 2020-02-11 |
| WO2018209052A1 (en) | 2018-11-15 |
| KR20200005721A (ko) | 2020-01-16 |
| RU2018146446A (ru) | 2021-06-10 |
| KR102662049B1 (ko) | 2024-05-23 |
| AU2018265258A1 (en) | 2019-01-17 |
| US20220169701A1 (en) | 2022-06-02 |
| AU2018265258B2 (en) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015599A (es) | Virus envuelto resistente a la inactivacion del complemento para el tratamiento del cancer. | |
| CY1122833T1 (el) | Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7 | |
| AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
| CO2018005306A2 (es) | Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia | |
| UY40420A (es) | Formulación que comprende una superóxido dismutasa | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| PE20170291A1 (es) | Vacunas contra virus de influenza y usos de las mismas | |
| CL2017001070A1 (es) | Variantes de interferon a2b | |
| MX380658B (es) | Variantes de region fc con union mejorada de la proteina a. | |
| CO2017002166A2 (es) | Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa | |
| MX395275B (es) | Construcciones con un dominio sirp-alfa o sus variantes | |
| MX2017011847A (es) | Modulación de inmunidad tumoral por liberación de o2 mediada por proteína. | |
| MX2017008449A (es) | Polipeptido de pirina y modulacion inmune. | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
| MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). | |
| AR132574A2 (es) | UN PÉPTIDO DE FUSIÓN QUE COMPRENDE UNA ISOFORMA DEL RECEPTOR II DE TGF b FUSIONADA A UN LIGANDO, POLINUCLEÓTIDO QUE LO EXPRESA, VECTOR Y CÉLULA | |
| PE20180162A1 (es) | Polipeptidos dirigidos a la fusion de vih | |
| MX2023014326A (es) | Peptidos y metodos de uso. | |
| BR112017005338A2 (pt) | composição contendo glicosaminoglicanos e proteínas | |
| UY36020A (es) | Antígeno de inhibina alfa, gen codificante de inhibina alfa, gen codificante de proteína de fusión, proceso de obtención del antígeno de inhibina alfa, composición antigénica, uso del antígeno de inhibina alfa y uso de la composición antigénica |